{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:02:36Z","timestamp":1779688956439,"version":"3.53.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Government-funded Project for Outstanding Talents in Clinical Medicine in 2024","award":["ZF2024072"],"award-info":[{"award-number":["ZF2024072"]}]},{"name":"Cultivation project of Precision Medicine Joint Fund of Natural Science Foundation of Hebei Province","award":["H2022206451"],"award-info":[{"award-number":["H2022206451"]}]},{"name":"Funded Project for Introducing Overseas Returnees in Hebei Province","award":["C20220348"],"award-info":[{"award-number":["C20220348"]}]},{"name":"Tracking Project of Applicable Medical Technologies in Hebei Province","award":["GZ2023060"],"award-info":[{"award-number":["GZ2023060"]}]},{"name":"Funded Project of Three Three Three Talent Project in Hebei Province","award":["C20221087"],"award-info":[{"award-number":["C20221087"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10620-025-09560-4","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T04:15:07Z","timestamp":1764044107000},"page":"1889-1900","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Silencing Clusterin Could Attenuate the Cell Properties of HCV Core Protein-Expressing HCC Cell Line"],"prefix":"10.1007","volume":"71","author":[{"given":"Fang","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjie","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxian","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingdi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiming","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2071-6307","authenticated-orcid":false,"given":"Na","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuemin","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"9560_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2174\/1874357901812010026","volume":"28","author":"A Petruzziello","year":"2018","unstructured":"Petruzziello A. Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma. Open Virol J. 2018;28:26\u201332.","journal-title":"Open Virol J."},{"key":"9560_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13027-016-0099-0","volume":"12","author":"A Petruzziello","year":"2016","unstructured":"Petruzziello A, Marigliano S, Loquercio G, Cacciapuoti C. Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer. 2016;12:53.","journal-title":"Infect Agent Cancer."},{"key":"9560_CR3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1681\/ASN.2013060577","volume":"26","author":"P Sansanwal","year":"2015","unstructured":"Sansanwal P, Li L, Sarwal MM. Inhibition of intracellular clusterin attenuates cell death in nephropathic cystinosis. J Am Soc Nephrol. 2015;26:612\u2013625.","journal-title":"J Am Soc Nephrol."},{"key":"9560_CR4","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Rivera C, Garcia MM, Molina-\u00c1lvarez M, Gonz\u00e1lez-Mart\u00edn C, Goicoechea C. Clusterin: Always protecting. Synthesis, function and potential issues. Biomed Pharmacother. 2021;134:111174.","DOI":"10.1016\/j.biopha.2020.111174"},{"key":"9560_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188500","volume":"1875","author":"PP Praharaj","year":"2021","unstructured":"Praharaj PP, Patra S, Panigrahi DP, Patra SK, Bhutia SK. Clusterin as modulator of carcinogenesis: A potential avenue for targeted cancer therapy. Biochim Biophys Acta Rev Cancer. 2021;1875:188500.","journal-title":"Biochim Biophys Acta Rev Cancer."},{"key":"9560_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2147\/OTT.S58622","volume":"20","author":"T Koltai","year":"2014","unstructured":"Koltai T. Clusterin: a key player in cancer chemoresistance and its inhibition. Onco Targets Ther. 2014;20:447\u2013456.","journal-title":"Onco Targets Ther."},{"key":"9560_CR7","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.humpath.2004.07.021","volume":"35","author":"YK Kang","year":"2004","unstructured":"Kang YK, Hong SW, Lee H, Kim WH. Overexpression of clusterin in human hepatocellular carcinoma. Hum Pathol. 2004;35:1340\u20131346.","journal-title":"Hum Pathol."},{"key":"9560_CR8","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1177\/03936155221101206","volume":"37","author":"G Gao","year":"2022","unstructured":"Gao G, Luan X. Diagnostic performance of clusterin in hepatocellular carcinoma: A meta-analysis. Int J Biol Markers. 2022;37:404\u2013411.","journal-title":"Int J Biol Markers."},{"key":"9560_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.55133\/eji.290204","volume":"29","author":"HS Rasmy","year":"2022","unstructured":"Rasmy HS, Mohammed HA, Mohammed ES, Ahmed ASM, Isaac A. Serum clusterin as a promising diagnostic and prognostic marker for hepatocellular carcinoma after locoregional treatment. Egypt J Immunol. 2022;29:26\u201340.","journal-title":"Egypt J Immunol."},{"key":"9560_CR10","first-page":"29","volume":"22","author":"N Fu","year":"2016","unstructured":"Fu N, Niu X, Wang Y, Du H, Wang B, Du J et al. Role of LncRNA-activated by transforming growth factor beta in the progression of hepatitis C virus-related liver fibrosis. Discov Med. 2016;22:29\u201342.","journal-title":"Discov Med."},{"key":"9560_CR11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/1357-2725(95)00027-M","volume":"27","author":"ME Rosenberg","year":"1995","unstructured":"Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol. 1995;27:633\u2013645.","journal-title":"Int J Biochem Cell Biol."},{"key":"9560_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117911","volume":"1","author":"N Fu","year":"2020","unstructured":"Fu N, Du H, Li D, Lu Y, Li W, Wang Y et al. Clusterin contributes to hepatitis C virus-related hepatocellular carcinoma by regulating autophagy. Life Sci. 2020;1:117911.","journal-title":"Life Sci."},{"key":"9560_CR13","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1600-0854.2007.00549.x","volume":"8","author":"P Nizard","year":"2007","unstructured":"Nizard P, Tetley S, Le Dr\u00e9an Y, Watrin T, Le Goff P, Wilson MR et al. Stress-induced retrotranslocation of clusterin\/ApoJ into the cytosol. Traffic. 2007;8:554\u2013565.","journal-title":"Traffic."},{"key":"9560_CR14","doi-asserted-by":"publisher","first-page":"12851","DOI":"10.1074\/jbc.M800403200","volume":"283","author":"H Ammar","year":"2008","unstructured":"Ammar H, Closset JL. Clusterin activates survival through the phosphatidylinositol 3-kinase\/Akt pathway. J Biol Chem. 2008;283:12851\u201312861.","journal-title":"J Biol Chem."},{"key":"9560_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1158\/1541-7786.MCR-09-0277","volume":"8","author":"A Zoubeidi","year":"2010","unstructured":"Zoubeidi A, Ettinger S, Beraldi E, Hadaschik B, Zardan A, Klomp LW et al. Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. Mol Cancer Res. 2010;8:119\u2013130.","journal-title":"Mol Cancer Res."},{"key":"9560_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12967-020-02262-7","volume":"18","author":"W Zheng","year":"2020","unstructured":"Zheng W, Yao M, Wu M, Yang J, Yao D, Wang L. Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT\/GSK-3\u03b2\/\u03b2-catenin axis. J Transl Med. 2020;18:81.","journal-title":"J Transl Med."},{"key":"9560_CR17","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s10238-022-00885-2","volume":"23","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Lv X, Chen L, Liu Y. The role and function of CLU in cancer biology and therapy. Clin Exp Med. 2023;23:1375\u20131391.","journal-title":"Clin Exp Med."},{"key":"9560_CR18","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.molcel.2023.02.024","volume":"83","author":"M Cie\u015bla","year":"2023","unstructured":"Cie\u015bla M, Ngoc PCT, Muthukumar S, Todisco G, Madej M, Fritz H, Dimitriou M, Incarnato D, Hellstr\u00f6m-Lindberg E, Bellodi C. m6A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis. Mol Cell. 2023;83:1165-1179.e11.","journal-title":"Mol Cell."},{"key":"9560_CR19","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1038\/s41467-021-24703-7","volume":"12","author":"J Xu","year":"2021","unstructured":"Xu J, Yang X, Deng Q, Yang C, Wang D, Jiang G, Yao X, He X, Ding J, Qiang J, Tu J, Zhang R, Lei QY, Shao ZM, Bian X, Hu R, Zhang L, Liu S. TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer. Nat Commun. 2021;12:4413.","journal-title":"Nat Commun."},{"key":"9560_CR20","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/abbs\/gms091","volume":"44","author":"Z Niu","year":"2012","unstructured":"Niu Z, Li X, Hu B, Li R, Wang L, Wu L et al. Small interfering RNA targeted to secretory clusterin blocks tumor growth, motility, and invasion in breast cancer. Acta Biochim Biophys Sin (Shanghai). 2012;44:991\u2013998.","journal-title":"Acta Biochim Biophys Sin (Shanghai)."},{"key":"9560_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1177\/147323001204000216","volume":"40","author":"J Li","year":"2012","unstructured":"Li J, Jia L, Zhao P, Jiang Y, Zhong S, Chen D. Stable knockdown of clusterin by vectorbased RNA interference in a human breast cancer cell line inhibits tumour cell invasion and metastasis. J Int Med Res. 2012;40:545\u2013555.","journal-title":"J Int Med Res."},{"key":"9560_CR22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/carcin\/bgt332","volume":"35","author":"A Radziwon-Balicka","year":"2014","unstructured":"Radziwon-Balicka A, Santos-Martinez MJ, Corbalan JJ, O\u2019Sullivan S, Treumann A, Gilmer JF et al. Mechanisms of platelet-stimulated colon cancer invasion: role of clusterin and thrombospondin 1 in regulation of the P38MAPK-MMP-9 pathway. Carcinogenesis. 2014;35:324\u2013332.","journal-title":"Carcinogenesis."},{"key":"9560_CR23","first-page":"7191","volume":"15","author":"J Zhong","year":"2018","unstructured":"Zhong J, Yu X, Dong X, Lu H, Zhou W, Li L et al. Therapeutic role of meloxicam targeting secretory clusterin-mediated invasion in hepatocellular carcinoma cells. Oncol Lett. 2018;15:7191\u20137199.","journal-title":"Oncol Lett."},{"key":"9560_CR24","doi-asserted-by":"publisher","first-page":"10594","DOI":"10.3390\/ijms130810594","volume":"13","author":"D Chen","year":"2012","unstructured":"Chen D, Wang Y, Zhang K, Jiao X, Yan B, Liang J. Antisense oligonucleotide against clusterin regulates human hepatocellular carcinoma invasion through transcriptional regulation of matrix metalloproteinase-2 and E-cadherin. Int J Mol Sci. 2012;13:10594\u201310607.","journal-title":"Int J Mol Sci."},{"key":"9560_CR25","doi-asserted-by":"publisher","first-page":"13135","DOI":"10.3390\/ijms222313135","volume":"22","author":"VA Arzumanian","year":"2021","unstructured":"Arzumanian VA, Kiseleva OI, Poverennaya EV. The Curious Case of the HepG2 Cell Line: 40 Years of Expertise. Int J Mol Sci. 2021;22:13135.","journal-title":"Int J Mol Sci."},{"key":"9560_CR26","first-page":"5","volume":"01","author":"RC Dong","year":"1980","unstructured":"Dong RC, Zhou RH, Lv FD, Tao WZ. Establishment of the SMMC-7721 human hepatocellular carcinoma cell line and preliminary observation of its biological characteristics][J. Journal of the Second Military Medical University 1980;01:5\u20139 (Chinese).","journal-title":"Journal of the Second Military Medical University"},{"key":"9560_CR27","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.18632\/oncotarget.3093","volume":"6","author":"C Wang","year":"2015","unstructured":"Wang C, Jin G, Jin H, Wang N, Luo Q, Zhang Y et al. Clusterin facilitates metastasis by EIF3I\/Akt\/MMP13 signaling in hepatocellular carcinoma. Oncotarget. 2015;6:2903\u20132916.","journal-title":"Oncotarget."},{"key":"9560_CR28","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/j.1440-1746.2009.06205.x","volume":"25","author":"Y Wang","year":"2010","unstructured":"Wang Y, Liu YH, Mai SJ, He LJ, Liao YJ, Deng HX et al. Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis. J Gastroenterol Hepatol. 2010;25:1123\u20131128.","journal-title":"J Gastroenterol Hepatol."},{"key":"9560_CR29","doi-asserted-by":"publisher","first-page":"8262","DOI":"10.3748\/wjg.v21.i27.8262","volume":"21","author":"P Xiu","year":"2015","unstructured":"Xiu P, Dong XF, Li XP, Li J. Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma. World J Gastroenterol. 2015;21:8262\u20138270.","journal-title":"World J Gastroenterol."},{"key":"9560_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11523-016-0448-3","volume":"12","author":"M Nishikawa","year":"2017","unstructured":"Nishikawa M, Miyake H, Gleave M, Fujisawa M. Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model. Target Oncol. 2017;12:69\u201379.","journal-title":"Target Oncol."},{"key":"9560_CR31","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.2174\/0929867326666190624161158","volume":"27","author":"M Yao","year":"2020","unstructured":"Yao M, Sai W, Zheng W, Wang L, Dong Z, Yao D. Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth. Curr Med Chem. 2020;27:3290\u20133301.","journal-title":"Curr Med Chem."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09560-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09560-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09560-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T05:06:27Z","timestamp":1779685587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09560-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["9560"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09560-4","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study received ethical approval from the institutional review board of The Third Hospital of Hebei Medical University No. 1\/016\/2014 and was performed in accordance with the Declaration of Helsinki (as revised in 2013). Written informed consent was obtained prior to sample collection which from each patient included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}